Assessing Breast Cancer Risk in Women
Am Fam Physician. 2008 Dec 15;78(12):1361-1366.
Understanding modifiable and nonmodifiable factors that increase or decrease breast cancer risk allows family physicians to counsel women appropriately. Nonmodifiable factors associated with increased breast cancer risk include advanced age, female sex, family history of breast cancer, increased breast density, genetic predisposition, menarche before age 12 years, and natural menopause after age 45 years. Hormonal factors associated with breast cancer include advanced age at first pregnancy, exposure to diethylstilbestrol, and hormone therapy. Environmental factors include therapeutic radiation. Obesity is also associated with increased rates of breast cancer. Factors associated with decreased cancer rates include pregnancy at an early age, late menarche, early menopause, high parity, and use of some medications, such as selective estrogen receptor modulators and, possibly, nonsteroidal anti-inflammatory agents and aspirin. No convincing evidence supports the use of dietary interventions for the prevention of breast cancer, with the exception of limiting alcohol intake.
The lifetime cumulative incidence rate of breast cancer ranges from one in seven to one in nine. This implies that if all women lived to age 85 years, approximately 12.5 percent would develop breast cancer. However, this risk is not distributed evenly among all women. Although statistical models can help physicians predict risk for some patients,1,2 risk assessment can be inconsistent for the same patient between different models.3,4 Of the risk factors most strongly associated with breast cancer, the two most notable are nonmodifiable: age and female sex. The incidence of breast cancer is significantly greater in postmenopausal women, and age is often the only known risk factor.
|Clinical recommendation||Evidence rating||References|
The decision to screen for breast cancer with mammography should be individualized based on risk factors and patient preferences.
The USPSTF recommends that women whose family history is associated with an increased risk for deleterious BRCA1 and BRCA2 mutations be referred for genetic counseling and evaluation for BRCA testing.
The USPSTF recommends against routine referral for genetic counseling and routine BRCA testing in women whose family history is not associated with an increased risk for deleterious BRCA1 and BRCA2 mutations.
Postmenopausal women should not take hormone therapy unless the benefits outweigh the apparent increased risk for breast cancer.
The USPSTF recommends that physicians discuss chemoprevention with women who are at high risk for breast cancer and at low risk for adverse effects from chemoprevention.
USPSTF = U.S. Preventive Services Task Force.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.
Understanding modifiable and nonmodifiable factors that increase or decrease breast cancer risk allows family physicians to counsel women appropriately (Table 1).5–46 It also allows women the opportunity to participate more actively in their health care. Although there is no definitive evidence on the effectiveness of risk factor modification for the prevention of breast cancer, patients can consider making behavioral changes that may reduce their risk of breast cancer (e.g., increasing exercise, decreasing alcohol consumption). Breast cancer screening with mammography is recommended in current guidelines,47 but some women may wish to discuss their individual risk before deciding whether to undergo screening. Additional information to assist physicians and patients in discussing breast cancer screening has been published.48
Risk Factors for Breast Cancer
Factors associated with decreased risk
Bilateral oophorectomy before 50 years of age*
First full-term pregnancy before 20 years of age*
Risk is reduced in women who are younger at time of first delivery (e.g., in women who are approximately 60 years of age at the time of breast cancer diagnosis, the OR is 0.68 if they delivered their first child at age 20 years versus 0.79 if they first delivered at age 35 years)9
Menarche at or after 14 years of age
Risk is reduced 10 percent per two-year delay in menarche after 12 years of age10
Risk progressively decreases with increasing number of full-term pregnancies (e.g., OR of developing breast cancer after one full-term pregnancy is 1.0 versus 0.70 after five full-term pregnancies)9,10
Use of selective estrogen receptor modulators*
Factors associated with increased risk
Cumulative incidence is 1.8 percent at 50 years of age
Cumulative incidence is 3.8 percent at 60 years of age
Cumulative incidence is 6.3 percent at 70 years of age
RR is increased 7.1 percent per drink consumed beyond one drink per day16
Proliferative with atypia: risk is increased 4.24-fold17
Proliferative without atypia: risk is increased 1.88-fold17
Established BRCA1 or BRCA2 mutation
Family history of breast cancer
Lifetime incidence of breast cancer is increased 5.5 percent in women with one affected first-degree relative and 13.3 percent in women with two22
History of ovarian cancer
Risk is increased
Hormone therapy: combination therapy with estrogen plus progesterone for more than five years increases risk more than the use of estrogen alone. Risk decreases five years after discontinuing therapy 24,25
Oral contraceptives: risk may be slightly increased with any use (OR, 1.19; 95% CI, 1.09 to 1.29), especially in parous women who use oral contraceptives for at least four years before their first full-term pregnancy (OR 1.52, 95% CI, 1.26 to 1.82)26,27
Increased breast density
Risk is increased28
Significant risk exists, especially in youngest treatment cohorts18
Menopause after 45 years of age
Risk is increased about 3 percent for each year menopause is delayed10
Factors with unknown or no apparent effect
Benign breast lesion
No effect in women with nonproliferative patterns17
Coffee, tea, and other caffeine-containing drinks: no effect29
Dietary phytoestrogens: no consistent effect30
Miscarriage and induced abortion
No consistent effect16
Factors That Increase Risk
NONMODIFIABLE RISK FACTORS
Reproductive and Hormonal Factors
Increased lifetime estrogen exposure is associated with increased rates of breast cancer. One theory about the hormonal influence on breast cancer risk is that breast development and maturation occur against a backdrop of cyclical and periodic hormonal influences on the breast that arise from endogenous or exogenous sources. Early menarche (i.e., before age 12 years) is associated with higher lifetime risk, but the greatest effect of early menarche may be in increased rates of breast cancer in premenopausal women; natural menopause (i.e., after age 45 years) is more strongly associated.10 The current median age of menopause is 51.4 years.49
Studies evaluating exogenous hormone administration have shown that although the absolute risk is low, the relative risk (RR) of breast cancer is increased in women who took diethylstilbestrol while pregnant (RR, 1.35; 95% confidence interval [CI], 1.05 to 1.74).50 However, their exposed daughters do not have an increased risk of breast cancer.51 The risk, if any, associated with infertility treatments has yet to be clarified.
Increased breast density is an independent nonmodifiable risk factor for breast cancer. Women who have a breast density of at least 75 percent on mammography have an odds ratio of breast cancer of 4.7 (95% CI, 3.0 to 7.4) compared with women who have breast density of 10 percent or less.28
Genetic Mutations and Family History
Known genetic mutations account for only 3 to 5 percent of all breast cancers.20–22 Although 60 percent of inherited cancers result from BRCA1 and BRCA2 mutations, there are at least 20 other genes that are known to contribute to inherited breast cancers.20–22 The cumulative lifetime risk of breast cancer attributable to genetic mutations is controversial, with estimates ranging from 25 to 85 percent. The BRCA genes are most prevalent in persons of Ashkenazi Jewish descent, but they have been found in multiple communities worldwide,23 so it is important not to assume the absence of a genetic component in women of other racial and ethnic heritages. Paternal family history is important when considering referral for genetic counseling, because BRCA mutations are inherited in an autosomal-dominant pattern and may increase susceptibility to other cancers. The U.S. Preventive Services Task Force (USPSTF) has recommended that physicians offer genetic testing to several groups of women (Table 2).2
Testing for BRCA Mutations: Recommendations From the USPSTF
Persons with a family history of breast or ovarian cancer in a relative with a known deleterious BRCA mutation should be tested.
Ashkenazi Jewish women should be tested if any first-degree relative (or two second-degree relatives on the same side of the family) have breast or ovarian cancer.
Non-Ashkenazi Jewish women should be tested if one of the following risk factors is present:
Two first-degree relatives with breast cancer, one of whom was diagnosed before 50 years of age
At least three first- or second-degree relatives with breast cancer, regardless of age at diagnosis
At least two first- or second-degree relatives with ovarian cancer, regardless of age at diagnosis
A combination of breast and ovarian cancers among first- and second-degree relatives
A first-degree relative with bilateral breast cancer
A first- or second-degree relative with both breast and
ovarian cancers, regardless of age at diagnosis
A male relative with a history of breast cancer
note: First-degree relatives are those who are one meiosis away from a particular family member (i.e., parent, sibling, offspring). Second- degree relatives include grandparents, aunts, uncles, and cousins.
USPSTF = U.S. Preventive Services Task Force.
Information from reference 2.
Benign breast disease and previous biopsy is associated with increased risk of breast cancer if proliferative patterns are seen. Atypia and a history of breast cancer are strongly associated with breast cancer.17 Therapeutic radiation, such as mantle radiation for Hodgkin's disease, significantly increases risk.18
POTENTIALLY MODIFIABLE R ISK FACTORS
During menopause and beyond, the risk associated with hormone therapy depends on the duration and formulation of therapy and, possibly, patient characteristics. Brief, intermittent use of estrogen alone does not increase risk. Recent long-term estrogen use (longer than five years) increases risk, and combined estrogen-progestin use increases risk greater than estrogen alone, especially in leaner women.24 The decrease in breast cancerincidence rates in 2003 may be attributed to cessation of hormone therapy after the results of the Women's Health Initiative were released in 2002.25 The associated risk appears to decrease significantly within two to three years after hormone therapy ends.
Women who become pregnant early in life (before age 20 years) and who carry the pregnancy to term have a decreased lifetime risk of breast cancer compared with nulliparous women, but they may have an increased risk for about 15 years after the pregnancy.9 Regardless of maternal age, increasing parity is associated with a decreased risk for breast cancer compared with nulliparity. Compared with nulliparous women, patients with more than five full-term pregnancies are about 50 percent less likely to develop breast cancer.10
Breastfeeding is associated with reduced rates of breast cancer over a woman's lifetime; the duration of breastfeeding is key. Early studies suggested that risk was reduced in premenopausal women who have breastfed,7 and extensive recent analysis shows a 4.3 percent RR reduction for every 12 months of breastfeeding.8
When counseling young women about breast cancer risk, it is reasonable to advise them of the benefits of breastfeeding in terms of breast cancer risk reduction, in addition to the multiple other benefits of breastfeeding.
MODIFIABLE RISK FACTORS
Many studies have assessed a wide range of dietary factors as they relate to breast cancer risk. One of the main challenges with these studies is the difficulty in accurately assessing diet in study subjects.
Alcohol consumption is associated with an increased risk of breast cancer. A pooled analysis of cohort studies showed that the RR of developing breast cancer is 1.09 in women who consume three fourths to one drink per day (95% CI, 1.04 to 1.13), and those who consume two to five drinks per day have an RR of 1.41 (95% CI, 1.18 to 1.69).16 The use of supplemental folate may reduce the incidence of breast cancer in persons who drink alcohol.52 Women should consider limiting alcohol intake to no more than one drink per day.
Behavioral and Lifestyle Factors
Breast cancer risk is lower in pre- and postmenopausal women who exercise regularly.11 Studies of obese women show that breast cancer incidence is reduced before menopause and increased after menopause; postmenopausal weight gain itself is a significant risk factor.53 One theory for this association is that obese women have increased production of endogenous estrogen in peripheral adipose tissue.19
Reproductive and Hormonal Factors
Elevated estradiol, testosterone, and sex hormone–binding globulin levels are not associated with increased breast cancer risk in postmenopausal women.54 In women with a family history of breast cancer5 and in women with BRCA1 and, possibly, BRCA2 mutations, bilateral oophorectomy is associated with reduced risk of breast cancer, especially if performed before age 40 years.6 However, no guidelines recommend prophylactic oophorectomies in women with genetic mutations.
Selective estrogen receptor modulators, particularly tamoxifen (Nolvadex, brand no longer available in the United States) and raloxifene (Evista), have been shown in randomized controlled trials to decrease breast cancer risk in higher-risk populations (i.e., women with significant family history, known BRCA mutations, and, possibly, mantle radiation exposure during childhood).13–15 The USPSTF recommends discussion of prophylactic therapy for women with known increased risk for breast cancer.55
Factors With Unknown Effects on Risk
Recent interest has prompted study of a subgroup of soy and related foods (e.g., chickpeas, red clover, tea, rye grains, broccoli) as sources of phytoestrogens. Studies within the European Prospective Investigation into Cancer and Nutrition (EPIC) study have not shown that phytoestrogens and isoflavones are associated with a significant reduction in breast cancer risk.30 An extensive pooled analysis of eight separate studies did not show any risk reduction associated with a wide variety of fruits and vegetables.33 The EPIC study reached similar conclusions.34 Although a diet containing fruits and vegetables benefits an overall healthy lifestyle, consumption does not affect breast cancer risk.
BEHAVIORAL AND LIFESTYLE FACTORS
Because aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin synthesis and, in turn, limit production of endogenous estrogen, it is possible that breast cancer risk can be reduced by regular use of these drugs. The effect of frequent (at least weekly) doses of aspirin and other NSAIDs on breast cancer risk is unclear.
Factors That Do Not Affect Risk
Dietary fat does not seem to increase the risk for breast cancer, regardless of the amount consumed, its source, or its fatty acid composition.31 A randomized controlled primary prevention trial within the Women's Health Initiative did not show that postmenopausal women who consumed a low-fat diet had a decreased risk of breast cancer.32 Numerous studies show that consumption of caffeine, coffee, and caffeinated tea does not increase the risk of breast cancer.29
REPRODUCTIVE AND HORMONAL FACTORS
Miscarriages and induced abortions have no effect on breast cancer risk beyond the benefit caused by parity.46
The evidence on the effect of hormonal contraception is mixed. A recent meta-analysis of case-control studies showed that risk is slightly increased with any use,26 whereas other well-designed studies have shown no effect on a woman's risk of developing breast cancer.27 Any risk associated with newer injectable, implantable, transdermal, and intravaginal contraceptives, which offer decreased dosage but achieve higher serum concentrations of the drug, has not been determined.
1. American Cancer Society. Cancer Facts and Figures, 2008. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed November 19, 2008.
2. Nelson HD, Huffman LH, Fu R, Harris EL, for the USPSTF. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force [published correction appears in Ann Intern Med. 2005;143(7):547] Ann Intern Med. 2005;143(5):362–379.
3. Claus EB. Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians Fam Cancer. 2001;1(3–4):197–206.
4. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention J Natl Cancer Inst. 2001;93(5):358–366.
5. Olson JE, Sellers TA, Iturria SJ, Hartmann LC. Bilateral oopherectomy and breast cancer risk reduction among women with a family history Cancer Detect Prev. 2004;28(5):357–360.
6. Eisen A, Lubinski J, Klijn J, et al. Breast cancer following bilateral oopherectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study J Clin Oncol. 2005;23(30):7491–7496.
7. Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and a reduced risk of premenopausal breast cancer N Engl J Med. 1994;330(2):81–87.
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease Lancet. 2002;360(9328):187–195.
9. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth N Engl J Med. 1994;331(1):5–9.
10. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer Epidemiol Rev. 1993;15(1):36–47.
11. McTiernan A, Kooperberg C, White E, et al., for the Women's Health Initiative Cohort Study. Recreational physical activity and the risk of breast cancer in postmenopausal women JAMA. 2003;290(10):1331–1336.
12. McTiernan A. Physical activity and the prevention of breast cancer Medscape Womens Health. 2000;5(5):E1.
13. Biglia N, Defabiani E, Ponzone R, Mariani L, Marenco D, Sismondi P. Management of risk of breast carcinoma in postmenopausal women Endocr Relat Cancer. 2004;11(1):69–83.
14. Eng-Wong J, Zujewski JA. Raloxifene and its role in breast cancer prevention Expert Rev Anticancer Ther. 2004;4(4):523–532.
15. Vogel VG, Costantino JP, Wickerham DL, et al., National Surgical Adjuvant Breast and Bowel Project. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [published corrections appear in JAMA. 2006;296(24):2926 and JAMA. 2007;298(9):973] JAMA. 2006;295(23):2727–2741.
16. Hamajima N, Hirose K, Tajima K, et al., for the Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease Br J Cancer. 2002;87(11):1234–1245.
17. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer N Engl J Med. 2005;353(3):229–237.
18. Laden F, Hunter DJ. Environmental risk factors and female breast cancer Annu Rev Public Health. 1998;19:101–123.
19. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer J Mammary Gland Biol Neoplasia. 2002;7(1):3–15.
20. Hartman AR. The problems with risk selection; scientific and psychosocial aspects Recent Results Cancer Res. 2005;166:125–144.
21. Dumitrescu RG, Cotarla I. Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med. 2005;9(1):208–221.
22. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease Lancet. 2001;358(9291):1389–1399.
23. Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers Int J Clin Oncol. 2004;9(4):270–282.
24. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer [published correction appears in Lancet. 1997;350(9089):1484] Lancet. 1997;350(9084):1047–1059.
25. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States N Engl J Med. 2007;356(16):1670–1674.
26. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis Mayo Clin Proc. 2006;81(10):1290–1302.
27. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer N Engl J Med. 2002;346(26):2025–2032.
28. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer N Engl J Med. 2007;356(3):227–236.
29. Michels KB, Holmberg L, Bergkvist L, Wolk A. Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women Ann Epidemiol. 2002;12(1):21–26.
30. Keinan-Boker L, van Der Schouw YT, Grobbee DE, Peeters PH. Dietary phytoestrogens and breast cancer risk Am J Clin Nutr. 2004;79(2):282–288.
31. Steiner E, Klubert D, Hayes M, Hamilton A, Kolasa K. Clinical inquiries. Does a low-fat diet help prevent breast cancer? J Fam Pract. 2007;56(7):583–584.
32. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial JAMA. 2006;295(6):629–642.
33. Smith-Warner SA, Spiegelman D, Yuan SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies JAMA. 2001;285(6):769–776.
34. van Gils CH, Peeters PH, Bueno-de-Mesquita HB, et al. Consumption of vegetables and fruits and risk of breast cancer JAMA. 2005;293(2):183–193.
35. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk: review of the epidemiological evidence IARC Sci Publ. 2002;156:331–336.
36. Kaye JA, Jick H. Antibiotics and the risk of breast cancer Epidemiology. 2005;16(5):688–690.
37. García Rodríguez LA, González-Pérez A. Use of antibiotics and risk of breast cancer Am J Epidemiol. 2005;161(7):616–619.
38. Didham RC, Reith DM, McConnell DW, Harrison KS. Antibiotic exposure and breast cancer in New Zealand Breast Cancer Res Treat. 2005;92(2):163–167.
39. Sørensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA. Use of antibiotics and risk of breast cancer: a population-based case-control study Br J Cancer. 2005;92(3):594–596.
40. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer JAMA. 2004;291(7):827–835.
41. Jacobs EJ, Thun MJ, Connell CJ, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort Cancer Epidemiol Biomarkers Prev. 2005;14(1):261–264.
42. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status J Natl Cancer Inst. 2005;97(11):805–812.
43. Harris RE, Chlebowski RT, Jackson RD, et al., for the Women's Health Initiative. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative Cancer Res. 2003;63(18):6096–6101.
44. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk Oncology. 2005;68(1):40–47.
45. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk JAMA. 2004;291(20):2433–2440.
46. Beral V, Bull D, Doll R, Peto R, Reeves G, for the Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries Lancet. 2004;363(9414):1007–1016.
47. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force Ann Intern Med. 2002;137(5 pt 1):347–360.
48. Knutson D, Steiner E. Screening for breast cancer: current recommendations and future directions Am Fam Physician. 2007;75(11):1660–1666.
49. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia, Pa.: Lippincott, Williams & Wilkins; 2005.
50. Colton T, Greenberg ER, Noller K, et al. Breast cancer in mothers prescribed diethystilbesterol in pregnancy. Further follow-up JAMA. 1993;269(16):2096–2100.
51. Hatch EE, Palmer JR, Titus-Ernstoff L, et al. Cancer risk in women exposed to diethylstilbesterol in utero JAMA. 1998;280(7):630–634.
52. Zhang SM. Role of vitamins in the risk, prevention, and treatment of breast cancer Curr Opin Obstet Gynecol. 2004;16(1):19–25.
53. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk JAMA. 1997;278(17):1401–1411.
54. Beattie MS, Costantino JP, Cummings SR, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1) J Natl Cancer Inst. 2006;98(2):110–115.
55. U.S. Preventive Services Task Force. Preventive medication: breast cancer. http://www.ahrq.gov/clinic/uspstf/uspsbrpv.htm#summary. Accessed November 17, 2007.
56. Nagata C, Mizoue T, Tanaka K, et al., for the Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Tobacco smoking and breast cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population Jpn J Clin Oncol. 2006;36(6):387–394.
57. Johnson KC. Accumulating evidence on passive and active smoking and breast cancer risk Int J Cancer. 2005;117(4):619–628.
Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.